Longwood Fund III, L.P. 3
3 · Werewolf Therapeutics, Inc. · Filed Apr 29, 2021
Insider Transaction Report
Form 3
Longwood Fund III GP, LLC
10% Owner
Holdings
- (indirect: See footnote)
Series A Preferred Stock
→ Common Stock (1,071,127 underlying) - (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (355,955 underlying)
Footnotes (3)
- [F1]The Series A Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]These securities are held of record by Longwood Fund III, L.P. ("Longwood III"). Longwood Fund III GP, LLC ("Longwood III GP") is the general partner of Longwood III. Voting, investment and dispositive decisions at Longwood III GP with respect to the securities held by Longwood III are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood III GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood III and as a result may be deemed to have beneficial ownership over such securities. Longwood III GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood III, except to the extent of their respective pecuniary interests therein.
- [F3]The Series B Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.